{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:18Z","timestamp":1793003658301,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40265-026-02367-1","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:26:04Z","timestamp":1789187164000},"page":"1941-1952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Doravirine\/Islatravir: First Approval"],"prefix":"10.1007","volume":"86","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"10528","key":"2367_CR1","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S0140-6736(25)02167-1","volume":"407","author":"V Estrada","year":"2026","unstructured":"Estrada V, Cabello-Clotet N. Beyond integrase: the rise of doravirine and islatravir in HIV management. Lancet. 2026;407(10528):551\u20133.","journal-title":"Lancet"},{"issue":"10148","key":"2367_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(18)31311-4","volume":"392","author":"J Ghosn","year":"2018","unstructured":"Ghosn J, Taiwo B, Seedat S, et al. HIV. Lancet. 2018;392(10148):685\u201397.","journal-title":"Lancet"},{"issue":"12","key":"2367_CR3","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1016\/S2352-3018(22)00249-1","volume":"9","author":"KM Gibas","year":"2022","unstructured":"Gibas KM, Kelly SG, Arribas JR, et al. Two-drug regimens for HIV treatment. Lancet HIV. 2022;9(12):e868\u201383.","journal-title":"Lancet HIV"},{"key":"2367_CR4","unstructured":"MSD K.K. IDVYNSO \u30a4\u30c9\u30d3\u30f3\u30bd\u00ae combination tablets: Japanese prescribing information. Tokyo: MSD K.K.; 2026."},{"key":"2367_CR5","unstructured":"MSD K.K. Approval obtained for \"IDVYNSO\u00ae Combination Tablets,\" an HIV-1 infection treatment drug administered orally once daily: a combination tablet containing islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI) with a novel mechanism of action, and doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) [media release]. 6 Mar 2026. https:\/\/www.msd.co.jp\/news\/product-news-20260306\/."},{"key":"2367_CR6","unstructured":"Merck Sharp & Dohme. IDVYNSOTM (doravirine and islatravir) tablets, for oral use: US prescribing information. 2026. https:\/\/www.fda.gov\/. Accessed 25 Jun 2026."},{"key":"2367_CR7","unstructured":"Merck & Co., Inc.,. FDA approves Merck\u2019s once-daily IDVYNSO\u2122 (doravirine\/islatravir) [media release]. 21 Apr 2026. https:\/\/www.merck.com\/."},{"key":"2367_CR8","unstructured":"Merck Canada Inc. IDVYNSO\u00ae (doravirine and islatravir tablets for oral use, 100 mg doravirine and 0.25 mg islatravir): Canadian product monograph. 2026. https:\/\/www.canada.ca\/en\/health-canada. Accessed 25 Jun 2026."},{"key":"2367_CR9","unstructured":"Yamasa Corporation. Yamasa\u2019s R&D leads to U.S. FDA approval of HIV-1 treatment over 380 years of history and innovation contributing to healthcare [media release]. 18 May 2026. https:\/\/www.yamasa-biochem.com\/en\/."},{"key":"2367_CR10","unstructured":"Merck & Co., Inc.,. Merck signs two deals for novel HIV drug candidates and initiates phase II clinical trial of MK-1439 for HIV [media release]. 24 July 2012. https:\/\/www.merck.com\/news\/merck-signs-two-deals-for-novel-hiv-drug-candidates-and-initiates-phase-ii-clinical-trial-of-mk-1439-for-hiv\/."},{"key":"2367_CR11","unstructured":"US FDA. Doravirine\/islatravir: clinical microbiology\/virology review(s) 2025. https:\/\/www.fda.gov\/. Accessed 30 Jun 2026."},{"key":"2367_CR12","unstructured":"Calmy A, Colson A, Koethe JR, et al. Evaluation of fasting lipids and insulin resistance after switch to doravirine\/islatravir (100 mg\/0.25 mg) once daily: week 48 results from two randomized phase 3 studies in adults living with HIV-1 [abstract no. MeP21.4]. HIV Med. 2025;26(Suppl 4):203\u20104."},{"issue":"10528","key":"2367_CR13","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0140-6736(25)01945-2","volume":"407","author":"C Orkin","year":"2026","unstructured":"Orkin C, Mngqibisa R, Velez JD, et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet. 2026;407(10528):599\u2013610.","journal-title":"Lancet"},{"issue":"10528","key":"2367_CR14","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(25)01948-8","volume":"407","author":"AE Colson","year":"2026","unstructured":"Colson AE, Mills AM, Ramgopal MN, et al. Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trial. Lancet. 2026;407(10528):611\u201321.","journal-title":"Lancet"},{"key":"2367_CR15","unstructured":"Orkin C, Mngqibisa R, Velez JD, et al. Switch to DOR\/ISL (100\/0.25 mg) QD from oral ART: week 96 update from an open-label phase III study [abstract no. 515]. Topics in Antiviral Medicine. 2026;34(1):164."},{"key":"2367_CR16","unstructured":"Colson A, Mills AM, Ramgopal M, et al. Switch to DOR\/ISL (100\/0.25 mg) QD from BIC\/FTC\/TAF: 96-week update from a blinded phase III study [abstract no. 514 plus poster]. Topics in Antiviral Medicine. 2026;34(1):163-4."},{"key":"2367_CR17","doi-asserted-by":"crossref","unstructured":"Mngqibisa R, Kassim S, McDonald C, et al. Safety and efficacy of doravirine\/islatravir (DOR\/ISL) 100\/0.25 mg once daily (QD) after ISL dose reduction from 0.75 mg: week 48 results from an open-label phase 3 study [abstract no. P-369]. Open Forum Infectious Diseases. 2026;13(Suppl 1):S362.","DOI":"10.1093\/ofid\/ofaf695.587"},{"issue":"6","key":"2367_CR18","doi-asserted-by":"publisher","first-page":"e369","DOI":"10.1016\/S2352-3018(24)00031-6","volume":"11","author":"JM Molina","year":"2024","unstructured":"Molina JM, Rizzardini G, Orrell C, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial. Lancet HIV. 2024;11(6):e369\u201379.","journal-title":"Lancet HIV"},{"issue":"6","key":"2367_CR19","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(24)00030-4","volume":"11","author":"AM Mills","year":"2024","unstructured":"Mills AM, Rizzardini G, Ramgopal MN, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2024;11(6):e357\u201368.","journal-title":"Lancet HIV"},{"key":"2367_CR20","doi-asserted-by":"crossref","unstructured":"Molina JM, Rizzardini G, Kassim S, et al. Switch to fixed-dose doravirine (100 mg) with islatravir (0.75 mg) once daily in adults with HIV-1 virologically suppressed on antiretroviral therapy: week 96 results of a randomized, open-label, phase 3 trial [abstract no. eP.A.095]. HIV Med. 2023;24(Suppl 5):185\u20137.","DOI":"10.1016\/S2352-3018(24)00031-6"},{"key":"2367_CR21","doi-asserted-by":"crossref","unstructured":"Paredes R, Mills AM, Rizzardini G, et al. Switch to fixed-dose doravirine\/islatravir (100\/0.75 mg) once daily in adults with HIV-1 virologically suppressed on bictegravir\/emtricitabine\/tenofovir alafenamide: week 96 results of a phase 3, randomized, double-blind, non-inferiority trial [abstract no. PS1.O1 plus presentation]. HIV Med. 2023;24(Suppl 5):185\u20136.","DOI":"10.1016\/S2352-3018(24)00030-4"},{"issue":"2","key":"2367_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/QAD.0000000000004367","volume":"40","author":"A Carr","year":"2026","unstructured":"Carr A, Mngqibisa R, Khaertynova I, et al. Efficacy and safety of doravirine\/islatravir in heavily treatment-experienced participants living with HIV-1: results from a randomized trial. AIDS. 2026;40(2):189\u201397.","journal-title":"AIDS"},{"issue":"7","key":"2367_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(26)00033-0","volume":"13","author":"JK Rockstroh","year":"2026","unstructured":"Rockstroh JK, Kassim S, Paredes R, et al. Fixed-dose daily doravirine (100 mg) with islatravir (0.25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial. Lancet HIV. 2026.13(7):e440\u2013e51.","journal-title":"Lancet HIV"},{"issue":"2","key":"2367_CR24","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/cid\/ciaf077","volume":"81","author":"JK Rockstroh","year":"2025","unstructured":"Rockstroh JK, Paredes R, Cahn P, et al. Doravirine\/islatravir (100\/0.75 mg) once-daily compared with bictegravir\/emtricitabine\/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, noninferiority trial. Clin Infect Dis. 2025;81(2):322\u201332.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2367_CR25","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2352-3018(21)00021-7","volume":"8","author":"JM Molina","year":"2021","unstructured":"Molina JM, Yazdanpanah Y, Afani Saud A, et al. Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. Lancet HIV. 2021;8(6):e324\u201333.","journal-title":"Lancet HIV"},{"issue":"1","key":"2367_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/QAI.0000000000002879","volume":"91","author":"JM Molina","year":"2022","unstructured":"Molina JM, Yazdanpanah Y, Afani Saud A, et al. Efficacy and safety of oral islatravir once daily in combination with doravirine through 96 weeks for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine. J Acquir Immune Defic Syndr. 2022;91(1):68\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2367_CR27","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT04295772. 2024. https:\/\/clinicaltrials.gov\/study\/NCT04295772. Accessed 25 Jun 2026."},{"key":"2367_CR28","unstructured":"Merck & Co., Inc.,. Merck announces clinical holds on studies evaluating islatravir for the treatment and prevention of HIV-1 infection [media release]. 13 Dec 2021. https:\/\/www.merck.com\/."},{"key":"2367_CR29","unstructured":"Squires KE, Correll TA, Robertson MN, et al. Effect of islatravir on total lymphocyte and lymphocyte subset counts [abstract no. 192]. In: Conference on Retroviruses and Opportunistic Infections. 2023."},{"key":"2367_CR30","unstructured":"Merck & Co., Inc.,. Merck to initiate new phase 3 clinical program with lower dose of daily oral islatravir in combination with doravirine for treatment of people with HIV-1 infection [media release]. 20 Sep 2022. https:\/\/www.merck.com\/."},{"key":"2367_CR31","unstructured":"Gallagher A. FDA approves doravirine\/islatravir as treatment for HIV. 2026. https:\/\/www.drugtopics.com\/view\/fda-approves-doravirine-islatravir-as-treatment-for-hiv. Accessed 1 Jul 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02367-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:01:58Z","timestamp":1793001718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2367"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02367-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"12 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The preparation of this review was not supported by any external funding.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}